#SFHS2610966AFrance Removes Three Hospital Medicines from the Add-On Reimbursement List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order removes three pharmaceutical products from France’s list of medicines that hospitals can bill separately on top of standard hospitalization payments. The change affects the listed Pfizer products REFACTO AF 250 IU and 500 IU, and CIS BIO INTERN’s YTRACIS solution, for all indications. Hospitals and billing teams should stop treating these products as separately billable under the add-on reimbursement list once the order applies.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Removes three pharmaceutical products from the hospital add-on reimbursement list
- Applies to REFACTO AF 250 IU, REFACTO AF 500 IU, and YTRACIS solution
- The removals apply for all indications of the listed products
Obligations
What this law requires
Do not bill REFACTO AF 250 IU, UCD code 3400893260395, separately in addition to hospitalization services under the list referred to in Article L. 162-22-7 of the Social Security Code, for any indication.
Do not bill REFACTO AF 500 IU, UCD code 3400893260456, separately in addition to hospitalization services under the list referred to in Article L. 162-22-7 of the Social Security Code, for any indication.
Do not bill YTRACIS solution FL 2 mL, UCD code 3400892512358, separately in addition to hospitalization services under the list referred to in Article L. 162-22-7 of the Social Security Code, for any indication.